What is NDC 83831-153?

83831-153 is the product NDC for Navitrux (fosaprepitant), Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by AVYXA Pharma, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

AVYXA Pharma, LLC, NDC labeler code 83831. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Navitrux?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Navitrux NDC 83831-153 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)83831-153Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83831-0153Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
83831-153-01	8383101530183831015301	1 VIAL in 1 CARTON (83831-153-01) / 5 mL in 1 VIALMarketed from Jul 23, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Navitrux
Generic name (nonproprietary): fosaprepitant
Active ingredients: Fosaprepitant dimeglumine — 150 mg/5mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: AVYXA Pharma, LLCNDC labeler code 83831
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 220436
Marketing start: Jul 23, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
Identifiers: Product ID 83831-153_bc79f63b-8a05-41b5-a349-f71f1313e791SPL ID bc79f63b-8a05-41b5-a349-f71f1313e791SPL set ID a41b7c3a-1376-43a7-b5b9-6ba2eba1e169RxCUI 1731077, 2745874UNII D35FM8T64XUPC 0383831153016
Pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N483831015301 followed by a unit qualifier and the quantity

Package 83831-0153-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 29, 2026.

Indications (excerpt from the label)

NAVITRUX, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use NAVITRUX has not been studied for the treatment of established nausea and vomiting. NAVITRUX is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other a…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 83831-153

What is NDC 83831-153?: 83831-153 is the product NDC for Navitrux (fosaprepitant), Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by AVYXA Pharma, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Navitrux (Fosaprepitant).
What is the active ingredient?: Fosaprepitant dimeglumine.
Who is the labeler?: AVYXA Pharma, LLC, NDC labeler code 83831. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Navitrux?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Navitrux (Fosaprepitant) NDC 83831-153